China (Mainland) 
Ms.Yilia
USD $8.80-8.80 / Gram
USD $6.00-9.00 / Gram
USD $8.80-8.80 / Gram
USD $6.00-9.00 / Gram
USD $2.00-10.00 / Kilogram
USD $11,000.00-12,000.00 / Metric Ton
USD $10.00-100.00 / Kilogram
USD $2.00-10.00 / Kilogram
USD $11,000.00-12,000.00 / Metric Ton
1) rich experience
we specialize in this field for many years,our pharmaceutical raw materials exported to overseas, to
europe,africa,asia, americas and other country, and we have got very good feedback from our customers
,and established long friendly relations of cooperation.
2) great quality, purity and favorable
good quality is one of our secret success, welcome order the samples.
3) safest and fastest delivery
we have adequate stock,and can arranged within 24 hours when receive the payment.tracking number
would be informed quickly after shipment.
we have special way could ship 2kg to 20tons products a time. we offer melting powder into liquid service
.and ship the liquid in special bottles.
4) good after-sales service
tell the package update asap, and will try best solve when customer encountered various problems!
everything is for customers
our products and services will focus on the largest customer demand, we hold the greatest enthusiasm
and sincere cooperation with each customer.
all in all, high quality, best service, security shipping and competitive price are our perpetual pursuance.
quick detail:
| pirfenidone | cas 53179-13-8 | brand: network union |
| mw: 185.22 | msds: avaiable | |
| mf : c12h11no | sample: avaiable | |
| category:antiinflammatory agents | min order: 10grams | |
| quality standard : enterprise standard | place of origin:china | |
| introduction | uses: the new anti-fibrotic material, with broad-spectrum anti-lung, liver, kidney, heart, and peritoneal fibrosis | |
| character | white powder | |
| applications | pharmaceutical raw materials | |
product description:
pirfenidone (inn, ban) is an anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (ipf). it works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens i and ii.
it is a drug developed by several companies worldwide, including intermune inc. (now part of roche), shionogi ltd., and gni group ltd. in 2008, it was first approved in japan for the treatment of ipf after clinical trials, under the trade name of pirespa by shionogi & co. in october 2010, the indian company cipla launched it as pirfenex. in 2011, it was approved for use in europe for ipf; it was approved in canada in 2012 ; and was approved in the united states in october 2014 under the same name. in september 2011, the chinese state food and drug administration provided gni group ltd with new drug approval of pirfenidone in china, and later manufacture approval in 2013 under the trade name of etuary.
in 2014 it was approved in mexico under the name kitoscell lp, indicated for pulmonary fibrosis and liver fibrosis.there is also a topical form created for the treatment of abnormal wound healing processes.
application:
in vitro, pirfenidone can inhibit the uterine flesh tumour cells and leiomyoma cells proliferation. pirfenidone can inhibit the tgf - beta - 1 inducing fibroblast collagen formation. inhibition of pdgf, fgf and tgf - beta - 1 inducing fibroblast proliferation. in hamster model, pirfenidone, taken by mouth, that can the prevention and treatment of pulmonary fibrosis . pirfenidone can prevent the sclerosing peritonitis in rats induced by chemical, can also be keloid grafting for the treatment of nude mice. pirfenidone 0.01 1 mg/ml can suppress the matrix and dose dependent manner serum stimulate uterine fibroids and leiomyoma cell dna synthesis, the compound has no cytotoxic effect, has no effect on collagen mrna level also. pirfenidone in hamster pulmonary fibrosis model can reduce the disease before the collagen i mrna level enhancement, reduce the level of the lung hydroxyproline and malondialadehyde and lung preserved ammonia acyl hydroxylase activity.
packaging
shipping method
